Haisco(SZ:002653) Ge Long Hui A P P·2026-02-12 10:15Core Viewpoint - The company, Heisico (002653.SZ), plans to jointly invest with Helix (Chengdu) Pharmaceutical Technology Co., Ltd. to establish two subsidiaries focusing on advanced biopharmaceutical technologies [1] Group 1: Investment Details - The total investment for the establishment of the subsidiary Heisibiotechnology Co., Ltd. is 97 million RMB, with Heisico investing 87 million RMB for an 89.69% equity stake, while Helix invests 10 million RMB for a 10.31% stake [1] - The focus of Heisibiotechnology will be on cutting-edge areas such as ADC (Antibody-Drug Conjugates) and In Vivo CART (Chimeric Antigen Receptor T-cell Immunotherapy) [1] Group 2: Second Subsidiary Investment - The total investment for the establishment of the subsidiary Heisixinyuan Pharmaceutical Technology Co., Ltd. is 48.5 million RMB, with Heisico investing 43.5 million RMB for an 89.69% equity stake, while Helix invests 5 million RMB for a 10.31% stake [1] - Heisixinyuan will focus on research in new-generation technologies such as small nucleic acid drugs [1]